
biotech companies active in R&D
World’s most innovative economy for 16 consecutive years
invested in Swiss biotech in 2025
Switzerland’s life sciences ecosystem brings together pharmaceutical companies, biotech firms, startups and leading research institutions. Companies can access expertise and partners across the value chain, from R&D and advanced manufacturing to commercialization, within a strategically located European business environment.

Switzerland brings together global pharmaceutical companies, innovative biotech firms, specialized SMEs, startups and leading research institutions in a connected life sciences ecosystem. Companies can access experienced partners across the value chain, from R&D and manufacturing to licensing and commercialization. With its central location, advanced infrastructure, and efficient logistics, Switzerland supports streamlined and cost-effective supply chain management across Europe and beyond.

Strong intellectual property protection, internationally recognized quality standards and established regulatory expertise provide a reliable environment for knowledge-intensive companies. Switzerland supports biotech and pharmaceutical businesses in developing, protecting and bringing innovations to market. Switzerland has one of the highest numbers of biotech patents per capita, thanks to its straightforward and effective IP registration system.

Leading universities and research institutions work closely with industry to turn scientific discoveries into commercial applications. Technology transfer, collaborative R&D and targeted innovation support help companies advance new products and technologies. When it comes to clinical trials and drug development, Switzerland contributes more to the global clinical trial pipeline per capita than any other country.

Switzerland attracts and develops highly qualified scientific, technical and managerial talent. Leading universities, established life sciences companies and an international working environment give businesses access to the expertise they need to establish and grow their operations. Consistently ranked #1 in INSEAD’s Global Talent Competitiveness Index, Switzerland is widely regarded as the most attractive destination for qualified international professionals and executives.
Sophia Genetics, based in the Canton of Vaud, was founded in 2011 as a spin-off of EPFL. Through its AI platform it established the world’s largest data-driven medicine community network and now serves more than 750 institutions worldwide
BC Platforms is a global leader in healthcare data management, analytics, and access. The company has global operations with its headquarters in Zurich, Switzerland, is partnered by over 90 hospitals, biobanks, and research centers globally, and reaches over all continents.
Geneva University Hospital became the first hospital in Europe to utilize IBM’s AI technology Watson to optimize therapeutic options for patients.
Incyte, a U.S.-based biopharma company, focuses on treatments in oncology, inflammation, and autoimmunity, with its European headquarters and a manufacturing site in Switzerland.
The U.S. company Organon & Co focuses on women’s health and established its international HQ for marketing, quality, supply chain management, and commercial functions in Lucerne.
Lonza, headquartered in Basel, is a global leader in pharma and biotech manufacturing, offering services from drug development to large-scale production. In Visp (Valais), the company is investing CHF 650 million to build a next-generation mammalian facility.
